MARKET

GKOS

GKOS

Glaukos Corp
NYSE
63.89
+1.89
+3.05%
Closed 18:52 11/30 EST
OPEN
61.99
PREV CLOSE
62.00
HIGH
63.94
LOW
61.69
VOLUME
695.86K
TURNOVER
0
52 WEEK HIGH
80.28
52 WEEK LOW
40.45
MARKET CAP
3.12B
P/E (TTM)
-23.7748
1D
5D
1M
3M
1Y
5Y
Bullish Two Hundred Day Moving Average Cross - GKOS
NASDAQ · 1d ago
Biotech Stocks Facing FDA Decision In December 2023
NASDAQ · 2d ago
Truist starts Glaukos at buy, cites glaucoma market opportunity
Healthcare truist starts glaukos at buy, cites glaucoma market opportunity. Truist cites the company's glau coma treatment candidate idose, which is currently being reviewed by the fda. The investment firm says the product could open up a $4b+ sustained-release implant market opportunity for the company.
Seeking Alpha · 2d ago
Analyst Ratings for Glaukos
Glaukos has an average price target of $82.0 with a high of $90.00 and a low of $66.00. In the last 3 months, 5 analysts have offered 12-month price targets for glaukos. The company has observed the following analyst ratings in the last quarter.
Benzinga · 3d ago
Truist Securities Initiates Coverage On Glaukos with Buy Rating, Announces Price Target of $88
Benzinga · 3d ago
Optimistic Buy Rating for Glaukos Amidst Evolving Medicare Coverage and Growth Potential
TipRanks · 4d ago
Weekly Report: what happened at GKOS last week (1120-1124)?
Weekly Report · 5d ago
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
NASDAQ · 11/23 11:20
More
About GKOS
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. The Company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.